not sure about the “isn’t enough to make money” point…. Doesn’t CarT treatment costs run into hundreds of k - which suggests a few hundred patients receiving this treatment if available would be an extremely healthy level of (yearly) returns - loads of assumptions naturally, but I certainly don’t think they’re pursuing a commercial white elephant re GBM?
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-31
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $13.80M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.6¢ | $47.39K | 2.808M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 3652924 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 50487 | 1 |
View Market Depth
| Last trade - 15.36pm 11/06/2024 (20 minute delay) ? |
|
|||||
|
Last
1.6¢ |
Change
-0.001 ( 5.88 %) |
||||
| Open | High | Low | Volume | ||
| 1.7¢ | 1.7¢ | 1.6¢ | 2454706 | ||
| Last updated 15.36pm 11/06/2024 ? | |||||
| CHM (ASX) Chart |